## △ Psychiatrist.com



Neurologic and Neurocognitive > Dementia

This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher's **Terms & Conditions.** 

#### **ORIGINAL ARTICLES**

### Vagus Nerve Stimulation in Patients With Alzheimer's Disease: Additional Follow-Up Results of a Pilot Study Through 1 Year

Charley A. Merrill, PhD; Michael A. G. Jonsson, MD; Lennart Minthon, MD, PhD; Hasse Ejnell, MD, PhD; Hans C-son Silander, MD, PhD; Kaj Blennow, MD, PhD; Mats Karlsson, MD; Arto Nordlund, MA; Sindre Rolstad, MA; Siegbert Warkentin, PhD; Elinor Ben-Menachem, MD, PhD; and Magnus J. C. Sjögren, MD, PhD

Published: August 15, 2006

#### **ARTICLE ABSTRACT**

#### BACKGROUND:

Cognitive-enhancing effects of vagusnerve stimulation (VNS) have been reported during 6 months oftreatment in a pilot study of patients with Alzheimer's disease(AD). Data through 1 year of VNS (collected from June 2000 toSeptember 2003) are now reported.

#### **METHOD:**

All patients (N = 17) met the NationalInstitute of Neurological and Communicative Disorders and Strokeand the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD. Responder rates for the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Mini-Mental State Examination (MMSE) were measured as improvement or absence of decline from baseline. Global change, depressive symptoms, and quality of life were alsoassessed. Cerebrospinal fluid (CSF) levels for total tau, tauphosphorylated at Thr181 (phosphotau), and Abeta42 were measured by standardized enzyme-linked immunosorbent assay (ELISA).

### MOST POPULAR

#### **COMMENTARY**

rTMS for Treatment-Resistant Depression:
Mismatch of Evidence and Insurance Coverage
Policies

The authors argue that insurance companies' prior authorization process overly restricts...

J Clin Psychiatry 2023;84(3):22com14575

Cory R. Weissman and others

#### **ORIGINAL RESEARCH**

## Screening for Bipolar Disorder and Evaluating the RMS

Health care providers found the Rapid Mood Screener, a new bipolar I disorder screening to...

Prim Care Companion CNS Disord 2023;25(2):22m03322

Michael E. Thase and others

**ADVERTISEMENT** 

#### **RESULTS:**









## △ Psychiatrist.com

with AD and warrantfurther investigation.	
Quick Links: <b><u>Dementia</u></b> , <u><b>Neurologic and Neurocognitive</b></u>	
CONTINUE DE A DINO	

#### **CONTINUE READING...**

LOGIN >

Forgot your login?

Paid print subscriber?

SUBSCRIBE >

Subscribe to read the entire article

**BUY NOW** 

\$40.00 Buy this Article as a PDF

#### **NARRATIVE REVIEW**

## Collaborative Care Model Education Opportunities

The Collaborative Care Model (CoCM) is an evidence-based methodology to improve access to ...

Prim Care Companion CNS Disord 2023;25(2):22nr03421

Patrick A. Ho and others

#### **ORIGINAL RESEARCH**

# Efficacy of Lumateperone in Bipolar Depression With Mixed Features

Lumateperone significantly improved depression symptoms, disease severity, and quality of ...

J Clin Psychiatry 2023;84(3):22m14739

Roger S. McIntyre and others









## △ Psychiatrist.com

## up-to-date today!

SUBSCRIBE

Already registered? Sign In

Depression: Mismatch of Evidence and Insurance Coverage Policies in the United States

The authors argue that insurance companies' prior authorization process overly restricts access to rTMS, which has proven...

Read More...



© Copyright 2023

Physicians Postgraduate Press, Inc. Lifelong Learning for Clinicians

JCP ISSN: Online 1555-2101, Print 0160-6689 PCC ISSN: Online 2155-7780, Print 2155-7772 MedFair.com US Patent No. 684794

About Psychiatrist.com

About The Journal of Clinical Psychiatry About The Primary Care Companion for CNS Disorders

About CME Institute

Advertisers

Media Relations

Contact Us Customer Service

Reprints and Permissions

FAQs

Privacy Policy

Terms of Use







